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    实验结果显示，经高温分解法制备的油溶性磁纳米粒子粒径约为 4 nm，经
薄膜分散法制备的甲氨蝶呤修饰的阿霉素磁温敏脂质体有良好的超顺磁性，粒径
为 107.5 ± 1.19 nm，Zeta 电位为 16.8 ± 1.2 mV，稳定性良好，一周内粒径、
电位值和载药量均无显著性变化。相变温度在 45℃附近，24 h 处，45℃下阿霉













































    Nanotechnology, which has a history of about forty years, has an unparalleled 
impact on chemistry, materials science and medicine, especially for providing a novel 
way of thinking and important means for diagnosis and treatment of malignant tumors 
which is one of three major ills in the world. Compared with the conventional 
antitumor drug therapy regimen with insufficient drug concentration at target site, low 
curative effect, large side effect, and single model, the new therapeutic mode of 
nanomaterials loaded traditional antineoplastic drugs has obvious advantages, which 
could improve the targeting ability of traditional antineoplastic drugs, reduce the 
damage to normal tissues, and realize multi-mode diagnosis and treatment integration. 
Therefore, the precise administration of antitumor drugs to specific tumor sites has 
become a hot spot and difficult point in the research of nano drug delivery system in 
recent years. 
    In this study, methotrexate-modified (MTX) thermo-sensitive magnetoliposomes 
(MTX-MagTSLs) with both photo-thermo and magnetocaloric-induced drug release 
were designed. In particular, oleic acid modified magnetic nanoparticles (MNPs) and 
lipophilic fluorescent dye Cy5.5 were encapsulated in the bilayers of 
methotrexate-modified thermo-sensitive liposomes, then the doxorubicin (Dox) 
hydrochloride was loaded by using ammonium sulfate gradient loading method. In 
this nano drug delivery system, methotrexate and oil-soluble magnetic nanoparticles 
could be applied to folate receptor bio-targeting and magnetic targeting. Meanwhile, 
fluorescent dye Cy5.5 and magnetic nanoparticles can not only realize fluorescence 
imaging and magnetic resonance imaging (MRI) to determine the degree of 
aggregation of nanoparticles in the tumor site, but also provide a specific laser 
radiation region for rapid release of anticancer drug under an alternating magnetic 
field (AMF). Evaluate the prepared methotrexate-modified thermo-sensitive 
magnetoliposomes loaded doxorubicin hydrochloride comprehensively through 
















nanoparticles, determining the cell toxicity, intracellular drug uptake, as well as 
investigating the pharmacokenitics, bio-distribution, body toxicity and anti-tumor 
efficacy in vivo. 
    The experimental results showed that the magnetic nanoparticles prepared by a 
high temperature decomposition method had a size of about 4 nm, and the 
methotrexate-modified thermo-sensitive magnetoliposomes prepared by thin-film 
dispersion method had good superparamagnetism, the diameter was 107.5 ± 1.19 nm, 
the Zeta potential was 16.8 ± 1.2 mV, which showed good stability with no significant 
changes in one week. The phase change temperature (Tm) of thermo-sensitive 
liposomes was around 45℃, the release quantity of doxorubicin at 24 h under 45℃ is 
twice that under 37℃. Small animal imaging and magnetic resonance imaging in vivo 
proved that the prepared nanomaterials could be used in fluorescence imaging and 
magnetic resonance imaging T2 negative imaging well. In vitro cytotoxicity, cell 
uptake, drug distribution in vivo, and tumor therapy results showed that 
methotrexate-modified thermo-sensitive magnetoliposomes had superior targeting 
ability on cervical cancer cells (HeLa) and HeLa tumor-bearing mice. At the same 
time, the thermal absorption of nanoparticles excited by alternating magnetic field and 
near infrared light simultaneously was 4.2 times of that of exciting by alternating 
magnetic field or near-infrared light separately, which could reach the phase change 
temperature of the designed nanoparticles quickly within 5 minutes, achieving the 
rapid release of drug in the region of the tumor, and realizing the precision of the 
antitumor treatment ultimately. 
    In summary, the methotrexate-modified multifunctional thermo-sensitive 
magnetoliposomes nanoparticles prepared in this paper could achieve dual-mode 
targeting incorporating biological and magnetic targeting, dual-mode imaging 
including fluorescence imaging and magnetic resonance imaging, and dual-mode drug 
release under magnetocaloric and photothermal treatment, which improve the 
targeting, controlled release, and multiple imaging capabilities of the traditional 
















tumor diagnosis and treatment integration, providing a reference for the relevant 
research in this field. 
  


















中文名称 缩写 英文名称 
交变磁场 AMF Alternative magnetic feild 
人非小细胞肺癌细胞 A549 Adenocarcinomic alveolar basal epithelial 
恒定磁场 CMF Constant magnetic feild 
二甲基亚砜  DMSO Dimethyl sulfoxide 
阿霉素 Dox Doxorubicin 
高通透性和滞留效应 EPR Permeability and retention effect  
宫颈癌细胞 HeLa                Human cervical carcinoma 
磁热治疗 MHT Magnetic hyperthermia therapy 
磁纳米粒子 MNPs Magnetic nanoparticles 
磁共振成像 MRI Magnetic resonance imaging 
甲氨蝶呤 MTX Methotrexate 
磷酸盐缓冲液 PBS Phosphate buffered saline 
光热治疗 PTT Photothermal therapy 
扫描电镜 SEM Scanning electron microscopy 
透射电镜 TEM Transmission electron microscopy  
相变温度 Tm Phase change temperature 
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